JP2022536370A5 - - Google Patents

Info

Publication number
JP2022536370A5
JP2022536370A5 JP2021573797A JP2021573797A JP2022536370A5 JP 2022536370 A5 JP2022536370 A5 JP 2022536370A5 JP 2021573797 A JP2021573797 A JP 2021573797A JP 2021573797 A JP2021573797 A JP 2021573797A JP 2022536370 A5 JP2022536370 A5 JP 2022536370A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
antibody
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021573797A
Other languages
English (en)
Japanese (ja)
Other versions
JP7680967B2 (ja
JP2022536370A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/037781 external-priority patent/WO2020252471A1/en
Publication of JP2022536370A publication Critical patent/JP2022536370A/ja
Publication of JP2022536370A5 publication Critical patent/JP2022536370A5/ja
Priority to JP2025078346A priority Critical patent/JP2025121996A/ja
Application granted granted Critical
Publication of JP7680967B2 publication Critical patent/JP7680967B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021573797A 2019-06-14 2020-06-15 Pd-1に対する抗体およびその使用方法 Active JP7680967B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025078346A JP2025121996A (ja) 2019-06-14 2025-05-09 Pd-1に対する抗体およびその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962861643P 2019-06-14 2019-06-14
US62/861,643 2019-06-14
PCT/US2020/037781 WO2020252471A1 (en) 2019-06-14 2020-06-15 Antibodies against pd-1 and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025078346A Division JP2025121996A (ja) 2019-06-14 2025-05-09 Pd-1に対する抗体およびその使用方法

Publications (3)

Publication Number Publication Date
JP2022536370A JP2022536370A (ja) 2022-08-15
JP2022536370A5 true JP2022536370A5 (https=) 2023-06-21
JP7680967B2 JP7680967B2 (ja) 2025-05-21

Family

ID=73781315

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021573797A Active JP7680967B2 (ja) 2019-06-14 2020-06-15 Pd-1に対する抗体およびその使用方法
JP2025078346A Pending JP2025121996A (ja) 2019-06-14 2025-05-09 Pd-1に対する抗体およびその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025078346A Pending JP2025121996A (ja) 2019-06-14 2025-05-09 Pd-1に対する抗体およびその使用方法

Country Status (6)

Country Link
US (1) US20220275088A1 (https=)
EP (1) EP3982997A4 (https=)
JP (2) JP7680967B2 (https=)
AU (1) AU2020290971A1 (https=)
CA (1) CA3141628A1 (https=)
WO (1) WO2020252471A1 (https=)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5307708B2 (ja) * 2006-06-02 2013-10-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトil−6受容体に対する高親和性抗体
WO2010041060A1 (en) * 2008-10-08 2010-04-15 Medimmune Limited Targeted binding agents directed to heparanase and uses thereof 463
JO3182B1 (ar) * 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
EP2284193A1 (en) * 2009-08-10 2011-02-16 Kenta Biotech AG Human monoclonal antibody against S. aureus derived apha-toxin and its use in treating or preventing abscess formation
HK1200322A1 (en) * 2011-10-24 2015-08-07 Abbvie Inc. Immunobinders directed against sclerostin
TWI681969B (zh) * 2014-01-23 2020-01-11 美商再生元醫藥公司 針對pd-1的人類抗體
KR20180019725A (ko) * 2015-06-23 2018-02-26 메모리얼 슬로안-케터링 캔서 센터 신규의 피디 1 면역 조절제
WO2017024515A1 (en) * 2015-08-11 2017-02-16 Wuxi Biologics (Cayman) Inc. Novel anti-pd-1 antibodies
AU2016317915B2 (en) * 2015-09-01 2021-02-18 Agenus Inc. Anti-PD-1 antibodies and methods of use thereof
RU2656181C1 (ru) * 2016-07-13 2018-05-31 Закрытое Акционерное Общество "Биокад" Анти-pd-1-антитела, способ их получения и способ применения
EP3497124A1 (en) * 2016-08-12 2019-06-19 ARSANIS Biosciences GmbH Klebsiella pneumoniae o3 specific antibodies
CA3059542A1 (en) * 2017-04-12 2018-10-18 Pfizer Inc. Antibodies having conditional affinity and methods of use thereof
WO2019062755A1 (en) * 2017-09-29 2019-04-04 Wuxi Biologics (Shanghai) Co., Ltd. BISPECIFIC ANTIBODIES DIRECTED AGAINST EGFR AND PD-1
CA3119644A1 (en) * 2018-11-30 2020-06-04 Dana-Farber Cancer Institute, Inc. Chimeric antigen receptor factories and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2022515318A5 (https=)
JP2022541435A5 (https=)
JP7399852B2 (ja) 多重特異性抗体とその作製及び使用方法
JP2022512684A5 (https=)
JP2019513370A5 (https=)
JP2018532766A5 (https=)
JP2019524693A5 (https=)
JP2018523493A5 (https=)
JP2021522162A5 (https=)
JP2018532383A5 (https=)
JP2019519492A5 (https=)
IL271325B2 (en) Guidance and navigation control proteins and method of making and using thereof
IL302278A (en) Combination treatment
JP2018522888A5 (https=)
TW202144426A (zh) 四價雙特異性抗體、其製備方法和用途
IL295996A (en) Miniature guidance and navigation control (minignc) of antibody-like proteins and methods of production and use thereof
JP2023524102A5 (https=)
JP2023544294A5 (https=)
JP2024539630A5 (https=)
JP2023116543A5 (https=)
AU2020400801B2 (en) Anti-BCMA/anti-4-1BB bispecific antibodies and uses thereof
JP2022513729A5 (https=)
JP2022536913A5 (https=)
JP2024541476A5 (https=)
JP7730432B2 (ja) がん治療におけるpd-1シグナル阻害剤との組み合わせによる抗cldn4-抗cd137二重特異性抗体の使用